{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', \"The ICF and the assent form used by the Investigator for obtaining the pediatric patient's\", 'Informed Consent must be reviewed and approved by the Sponsor prior to submission to the', 'appropriate Ethics Committee (IRB/IEC)] for approval/favorable opinion.', 'In relation with the population of patients exposed in the trial, ie, pediatric/minor patients, the', 'IRB/IEC should ensure proper advice from specialist with pediatrics expertise (competent in the', 'area of clinical, ethical and psychosocial problems in the field of pediatrics) according to national', 'regulations. This should be documented.', 'Prior to and on the same date as the Screening Visit 1, and a patients registration in IVRS/IWRS,', 'the Investigator or designee must have collected the signed and completed ICF/IAF.', 'The main study informed consent form, the assent form for girls who have started menstruating,', \"to be used by the Investigator for obtaining the patient's/parent(s)/legal guardian(s) informed\", 'consent/assent as applicable per national requirements must be reviewed and approved by the', 'Sponsor prior to submission to the appropriate Ethics Committee (IRB/IEC) for', 'approval/favorable opinion.', 'In addition, for Brazil, a country-specific ICF will be issued for the collection of additional blood', 'samples for the assessment of pre and post Yellow Fever vaccination titers, dupilumab PK, and', \"ADA levels. Refusal to sign the additional ICF will not impact the patient's ability to receive\", 'Yellow Fever vaccination (Appendix N).', 'If the race/ethnic origin of the patients will be collected in the clinical trial, the scientific', 'justification should be specified in Section 14.5.', '12.3 HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARDIINDEPENDENT', 'ETHICS COMMITTEE (IRB/IEC)', 'As required by local regulation, the Investigator or the Sponsor must submit this clinical trial', 'protocol to the health authorities (competent regulatory authority) and the appropriate IRB/IEC,', 'and is required to forward to the respective other party a copy of the written and dated', 'approval/favorable opinion signed by the chairman with IRB/IEC composition.', 'Property of the Sanofi Group - strictly confidential', 'Page 124', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'The clinical trial (study number, clinical trial protocol title and version number), the documents', \"reviewed (clinical trial protocol, ICF, Investigator's Brochure and Investigator's curriculum vitae\", '[CV], etc) and the date of the review should be clearly stated on the written (IRB/IEC)', 'approval/favorable opinion.', 'The IMP will not be released at the study site and the Investigator will not start the study before', 'the written and dated approval/favorable opinion is received by the Investigator and the Sponsor.', 'During the clinical trial, any amendment or modification to the clinical trial protocol should be', 'submitted to the health authorities (competent regulatory authority), as required by local', 'regulation, in addition to the IRB/IEC before implementation, unless the change is necessary to', 'eliminate an immediate hazard to the patients, in which case the health authorities (competent', 'regulatory authority) and the IRB/IEC should be informed as soon as possible. They should also', 'be informed of any event likely to affect the safety of patients or the continued conduct of the', \"clinical trial, in particular any change in safety. All updates to the Investigator's Brochure will be\", 'sent to the IRB/IEC and to health authorities (competent regulatory authority), as required by', 'local regulation.', \"A progress report is sent to the IRB/IEC at least annually and a summary of the clinical trial's\", 'outcome at the end of the clinical trial.', 'Property of the Sanofi Group - strictly confidential', 'Page 125', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}